Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rockwell Medical (RMTI) Cash & Equivalents (2016 - 2025)

Rockwell Medical (RMTI) has disclosed Cash & Equivalents for 16 consecutive years, with $13.6 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Cash & Equivalents rose 10.31% year-over-year to $13.6 million, compared with a TTM value of $13.6 million through Sep 2025, up 10.31%, and an annual FY2024 reading of $15.7 million, up 74.35% over the prior year.
  • Cash & Equivalents was $13.6 million for Q3 2025 at Rockwell Medical, up from $12.5 million in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $35.7 million in Q1 2021 and bottomed at $6.6 million in Q1 2024.
  • Average Cash & Equivalents over 5 years is $15.2 million, with a median of $12.3 million recorded in 2024.
  • The sharpest move saw Cash & Equivalents crashed 72.72% in 2021, then surged 74.35% in 2024.
  • Year by year, Cash & Equivalents stood at $13.3 million in 2021, then decreased by 23.93% to $10.1 million in 2022, then dropped by 11.08% to $9.0 million in 2023, then surged by 74.35% to $15.7 million in 2024, then fell by 13.1% to $13.6 million in 2025.
  • Business Quant data shows Cash & Equivalents for RMTI at $13.6 million in Q3 2025, $12.5 million in Q2 2025, and $11.4 million in Q1 2025.